肿瘤药敏试验与临床病理及疗效的关系

The relationship among chemosensitivity test,clinic pathology and curative effect of tumor

目的从不同肿瘤患者、组织学来源和病理类型等方面探讨肿瘤药敏试验与恶性肿瘤化疗药物敏感性的关系,以及药敏试验对肿瘤患者选择不同化疗药物治疗的意义。方法回顾性分析本院1991～2006年用MTT法检测的468例恶性实体肿瘤细胞对不同化疗药物敏感性的阳性结果,研究其与临床治疗用药的关系,并观察远期生存率。结果同一种肿瘤的不同个体、5种不同组织来源的肿瘤、3种消化系统肿瘤和相同病理类型低分化腺癌的不同实体瘤之间对化疗药物的敏感性均不同(P<0.05)。胃癌、肺癌的3年生存率和卵巢癌的5年生存率敏感组高于对照组,但差异无统计学意义(P>0.05);肝癌5年生存率敏感组低于对照组,差异无统计学意义(P>0.05)。结论恶性肿瘤对化疗药物的敏感性不同,化疗药敏实验与临床常用有效药物相关性较好,有助于临床筛选有效药物,排除不敏感药物,有利于选择有效的化疗方案。

ObjectiveTo explore the susceptibility tests of antitumor drug in vitro and its significance in selecting chemotherapy drugs for patients with different tumors.Methods468 cases of malignant solid tumor from 1991 to 2006 tested by MTT were analyzed retrospectively.ResultsThe susceptibility of antitumor drug was different among the individuals that were with different histological sources and/or different types of tumor.Comparing to the control group,the drug-susceptive patents with gastric cancer or lung cancer had higher rate of 3-year survival,with ovarian cancer had higher rate of 5-year survival,with liver cancer had lower rate of 5-year survival,although all of these differences were not statistically significant.ConclusionsThe sensitivity of antitumor drug is different among individuals and tumors.MTT is correlated with clinical chemotherapy effect and is helpful in selecting effective antitumor drugs for different patients.